JP2013503901A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503901A5
JP2013503901A5 JP2012528084A JP2012528084A JP2013503901A5 JP 2013503901 A5 JP2013503901 A5 JP 2013503901A5 JP 2012528084 A JP2012528084 A JP 2012528084A JP 2012528084 A JP2012528084 A JP 2012528084A JP 2013503901 A5 JP2013503901 A5 JP 2013503901A5
Authority
JP
Japan
Prior art keywords
group
amino
pyridin
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012528084A
Other languages
English (en)
Japanese (ja)
Other versions
JP5868855B2 (ja
JP2013503901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/047800 external-priority patent/WO2011028995A1/en
Publication of JP2013503901A publication Critical patent/JP2013503901A/ja
Publication of JP2013503901A5 publication Critical patent/JP2013503901A5/ja
Application granted granted Critical
Publication of JP5868855B2 publication Critical patent/JP5868855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012528084A 2009-09-03 2010-09-03 チロシンキナーゼ調節剤としての化合物 Expired - Fee Related JP5868855B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US23960309P 2009-09-03 2009-09-03
US61/239,603 2009-09-03
US30661610P 2010-02-22 2010-02-22
US61/306,616 2010-02-22
US35669910P 2010-06-21 2010-06-21
US61/356,699 2010-06-21
US36053110P 2010-07-01 2010-07-01
US61/360,531 2010-07-01
PCT/US2010/047800 WO2011028995A1 (en) 2009-09-03 2010-09-03 Compounds as tyrosine kinase modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016001387A Division JP6109974B2 (ja) 2009-09-03 2016-01-06 チロシンキナーゼ調節剤としての化合物

Publications (3)

Publication Number Publication Date
JP2013503901A JP2013503901A (ja) 2013-02-04
JP2013503901A5 true JP2013503901A5 (https=) 2013-10-24
JP5868855B2 JP5868855B2 (ja) 2016-02-24

Family

ID=43086186

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012528084A Expired - Fee Related JP5868855B2 (ja) 2009-09-03 2010-09-03 チロシンキナーゼ調節剤としての化合物
JP2012528089A Pending JP2013503903A (ja) 2009-09-03 2010-09-03 チロシンキナーゼモジュレーターとしての化合物
JP2016001387A Expired - Fee Related JP6109974B2 (ja) 2009-09-03 2016-01-06 チロシンキナーゼ調節剤としての化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012528089A Pending JP2013503903A (ja) 2009-09-03 2010-09-03 チロシンキナーゼモジュレーターとしての化合物
JP2016001387A Expired - Fee Related JP6109974B2 (ja) 2009-09-03 2016-01-06 チロシンキナーゼ調節剤としての化合物

Country Status (19)

Country Link
US (5) US8809534B2 (https=)
EP (2) EP2473501B1 (https=)
JP (3) JP5868855B2 (https=)
KR (2) KR20120082890A (https=)
CN (2) CN102498114A (https=)
AU (2) AU2010289353B2 (https=)
BR (2) BR112012004843A2 (https=)
CA (2) CA2772625A1 (https=)
CL (2) CL2012000587A1 (https=)
ES (1) ES2730086T3 (https=)
IL (2) IL218332A0 (https=)
IN (1) IN2012DN02493A (https=)
MX (2) MX2012002591A (https=)
NZ (2) NZ598455A (https=)
PH (1) PH12014500281A1 (https=)
RU (2) RU2012112151A (https=)
SG (2) SG178965A1 (https=)
WO (2) WO2011029001A1 (https=)
ZA (2) ZA201201592B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9902709B2 (en) 2014-04-08 2018-02-27 Peking University Founder Group Co., Ltd. Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
ES2599458T3 (es) 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
CN105125547A (zh) 2009-05-07 2015-12-09 费瑞姆医药有限公司 苯氧基甲基杂环化合物
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
US8906944B2 (en) * 2009-09-03 2014-12-09 Allergan, Inc. Compounds as tyrosine kinase modulators
AU2010289353B2 (en) * 2009-09-03 2016-12-08 Allergan, Inc. Compounds as tyrosine kinase modulators
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9045493B2 (en) * 2012-02-09 2015-06-02 Merck Patent Gmbh Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
WO2015069287A1 (en) * 2013-11-08 2015-05-14 Allergan, Inc. Compounds as tyrosine kinase modulators
CA2932353A1 (en) 2013-12-13 2015-06-18 Steven P. Treon Methods to treat lymphoplasmacytic lymphoma
EP3079683A4 (en) * 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
CN104326985A (zh) * 2014-09-24 2015-02-04 安润医药科技（苏州）有限公司 利你法尼的制备方法
EP3715346B1 (en) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN107531679B (zh) * 2016-03-18 2021-07-02 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
CN107663202B (zh) * 2016-07-29 2020-09-04 西华大学 3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
EP3600333A4 (en) 2017-03-21 2020-11-25 The Scripps Research Institute CU AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS
PT3621960T (pt) 2017-05-11 2021-09-16 Bristol Myers Squibb Co Tienopiridinas e benzotiofenos úteis como inibidores de irak4
WO2018211442A1 (en) * 2017-05-18 2018-11-22 Pi Industries Ltd. Formimidamidine compounds useful against phytopathogenic microorganisms
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FI935279L (fi) 1991-05-29 1993-11-26 Pfizer Tricykliska polyhydroxyltyrosinkinasininhibitorer
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU9802198A (en) * 1997-10-21 1999-05-10 Pharmacia & Upjohn Company Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
AU9598601A (en) * 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
WO2002090352A2 (de) * 2001-05-08 2002-11-14 Schering Aktiengesellschaft Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
AU2002341881B2 (en) 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US20050058689A1 (en) 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
MXPA05009102A (es) * 2003-02-28 2006-05-31 Bayer Pharmaceuticals Corp Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos.
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
ES2314444T3 (es) * 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
MXPA06002256A (es) * 2003-08-29 2006-05-17 Pfizer Naftaleno carboxamidas y sus derivados utiles como agentes anti-angiogenicos.
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
CN101128454A (zh) * 2004-12-22 2008-02-20 阿斯利康(瑞典)有限公司 用作抗癌药物的吡啶羧酰胺衍生物
EP1846388A4 (en) * 2005-01-25 2011-12-07 Synta Pharmaceuticals Corp THIOPHEN COMPOUNDS FOR IGNITIONS AND THE IMMUNE SYSTEM APPLICATIONS
PL1848435T3 (pl) 2005-01-25 2016-08-31 Synta Pharmaceuticals Corp Związki przeciwko zapaleniom i zastosowania związane z odpornością
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
CA2610509A1 (en) * 2005-06-03 2006-12-14 Bayer Healthcare Ag 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
US20070155746A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
JP2009526761A (ja) * 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
JP2009533327A (ja) * 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤
AR060061A1 (es) * 2006-03-22 2008-05-21 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2008131276A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
NZ580660A (en) * 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
ES2593279T3 (es) 2007-08-29 2016-12-07 Methylgene Inc. Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados
PL2183254T3 (pl) * 2007-08-29 2017-10-31 Methylgene Inc Inhibitory aktywności białkowej kinazy tyrozynowej
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2009070328A1 (en) 2007-11-26 2009-06-04 The Regents Of The University Of California Modulators of the epidermal growth factor receptor (egfr) pathway for use in the treatment or prevention of substance abuse
WO2009103778A1 (en) * 2008-02-19 2009-08-27 Novasaid Ab Compounds and methods
NZ588355A (en) * 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US9006252B2 (en) * 2008-09-26 2015-04-14 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
US8906944B2 (en) * 2009-09-03 2014-12-09 Allergan, Inc. Compounds as tyrosine kinase modulators
AU2010289353B2 (en) * 2009-09-03 2016-12-08 Allergan, Inc. Compounds as tyrosine kinase modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9902709B2 (en) 2014-04-08 2018-02-27 Peking University Founder Group Co., Ltd. Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2013503901A5 (https=)
RU2012112151A (ru) Соединения как модуляторы тирозинкиназы
RU2482111C2 (ru) Соединения, обладающие противораковой активностью
RU2497813C2 (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
JP2010508338A5 (https=)
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2013503903A5 (https=)
RU2451674C2 (ru) Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1
JP2013517283A5 (https=)
JP2007519754A5 (https=)
JP2014511869A5 (https=)
JP2006500348A5 (https=)
RU2014142598A (ru) Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
JP2005511543A5 (https=)
RU2015133171A (ru) Бензиламиновые производные
JP2019537603A5 (https=)
CA2550596A1 (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
JP2019505595A5 (https=)
RU2013123057A (ru) N-бензил гетероциклические карбоксамиды
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
JP2010523644A5 (https=)
JP2018515489A5 (https=)